Docusign shares slump on billings miss, as revenue and profits top estimates

DocuSign shares fell over 17% after the company reported mixed fiscal Q1 earnings, with a billings miss and lowered fiscal 2026 billings guidance overshadowing beats on revenue and EPS. Q1 billings of $739.6 million missed estimates, and fiscal 2026 billings guidance was revised down to $3.285B-$3.339B, attributed to lower-than-expected early renewals. While revenue and EPS exceeded expectations, analysts remain cautious, citing macro headwinds and the need to regain confidence in DocuSign's AI strategy; Wedbush lowered its price target to $85 from $100.

Analysis

Docusign (DOCU) experienced a significant share price decline of over 17% following its fiscal first-quarter earnings report, primarily due to a miss on billings and a downward revision of its fiscal 2026 billings guidance. First-quarter billings reached $739.6 million, a 4% year-over-year increase, but fell short of both Street estimates ($746.2 million) and the company's own guidance ($741 million - $751 million); analysts attributed this to a faster-than-anticipated reduction in early renewals as sales focused on Identity and Access Management (IAM) expansion. Consequently, fiscal 2026 billings guidance was lowered to $3.285 billion - $3.339 billion, a reduction from its prior guidance though this revised range aligns with the Street estimate. Despite these billings headwinds, Docusign reported stronger-than-expected Q1 revenue of $763.7 million (up 8% YoY) and earnings per share of $0.90, surpassing estimates. Customer growth continued, reaching 1.71 million, with a stable net retention rate of 101% and its IAM platform noted as its fastest-growing offering. However, the severe market reaction underscores concerns about Docusign's future growth trajectory, with Wedbush maintaining a 'Neutral' rating and reducing its price target from $100 to $85, citing the need for Docusign's AI strategy to gain investor confidence amidst a challenging macroeconomic environment.

Key Decisions for Investors

• Investors should closely monitor Docusign's subsequent quarterly billings performance and management's commentary on early renewal trends and IAM adoption, as these are currently the primary drivers of investor sentiment and stock valuation.
• The successful execution and market traction of the new IAM platform, alongside a clearly articulated and demonstrably progressing AI strategy, will be critical catalysts for rebuilding investor confidence and justifying a re-rating of the stock.
• Given the significant stock price correction and lowered billings outlook, investors should exercise caution, reassess their risk tolerance relative to Docusign, and potentially await further evidence of stabilization in billings growth and a more convincing long-term growth narrative before initiating or adding to positions.